Globus strengthens position as UK's leading force in hand protection
Progressing after 15 years in partnership with Showa Glove Company, UK leader in advanced hand protection solutions, Globus (Shetland) Ltd has announced an exciting addition to its market-leading portfolio.
From 1 March 2010 Globus has taken over all Showabest activities in the UK and Ireland. The addition of unique chemical protection products and the world's most advanced disposable glove offer gives Globus the only product portfolio that can claim the original iconic styles that created totally new markets for their distribution partners.
Grip style gloves, Palm Fit technology, Dyneema cut protective gloves and the world's first and patented disposable nitrile glove were all created by the Showabest organisation.
Innovative sales & marketing techniques have seen Globus rise to the forefront of the hand protection sector. Its customers now look set to enjoy the benefits of an invigorated range supported by UK stock and extensive sales support infrastructure.
You may also like
Regulatory
3PBIOVIAN secures French CIR certification for Spain and Finland R&D sites
Read moreThe CDMO has obtained French Crédit d’Impôt Recherche (CIR) certification for its Pamplona and Turku sites, enabling French partners to access tax incentives when collaborating on recombinant protein and advanced therapy projects
Trending Articles
You may also like
Regulatory
3PBIOVIAN secures French CIR certification for Spain and Finland R&D sites
The CDMO has obtained French Crédit d’Impôt Recherche (CIR) certification for its Pamplona and Turku sites, enabling French partners to access tax incentives when collaborating on recombinant protein and advanced therapy projects
Regulatory
Shilpa Medicare targets US approval for extended-release Ondansetron injection for CINV
Shilpa Medicare plans to pursue US approval and licensing partners for OERIS after a Phase III study in India met all primary and secondary endpoints and showed a strong safety profile in chemotherapy-induced nausea and vomiting
Regulatory
Ascletis secures FDA IND clearance for Phase II Study of oral GLP-1 candidate in type 2 diabetes
Ascletis has received US FDA IND clearance to begin a 13-week Phase II trial of ASC30, its oral small-molecule GLP-1 receptor agonist, evaluating efficacy, safety and tolerability in people with type 2 diabetes
Regulatory
Novo Nordisk wins positive ruling for semaglutide compound patent from China’s Supreme People’s Court
The company has welcomed a decision by China’s Supreme People’s Court affirming the validity of its semaglutide compound patent, strengthening confidence for foreign drugmakers operating in the Chinese market